The stock has a 36-month beta value of -0.65. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for AMLX is 41.21M, and at present, short sellers hold a 2.45% of that float. On November 07, 2024, the average trading volume of AMLX was 1.30M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
AMLX) stock’s latest price update
The stock of Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) has increased by 7.23 when compared to last closing price of 6.22. Despite this, the company has experienced a 23.52% gain in its stock price over the last five trading sessions. fool.com reported 2024-10-18 that The company seems to have a winner on its hands with a drug that targets a rare genetic disorder.
AMLX’s Market Performance
AMLX’s stock has risen by 23.52% in the past week, with a monthly rise of 96.76% and a quarterly rise of 251.05%. The volatility ratio for the week is 6.87% while the volatility levels for the last 30 days are 11.29% for Amylyx Pharmaceuticals Inc The simple moving average for the past 20 days is 34.31% for AMLX’s stock, with a 42.17% simple moving average for the past 200 days.
Analysts’ Opinion of AMLX
Many brokerage firms have already submitted their reports for AMLX stocks, with BofA Securities repeating the rating for AMLX by listing it as a “Buy.” The predicted price for AMLX in the upcoming period, according to BofA Securities is $10 based on the research report published on October 23, 2024 of the current year 2024.
Mizuho, on the other hand, stated in their research note that they expect to see AMLX reach a price target of $4, previously predicting the price at $32. The rating they have provided for AMLX stocks is “Neutral” according to the report published on March 18th, 2024.
Robert W. Baird gave a rating of “Neutral” to AMLX, setting the target price at $4 in the report published on March 11th of the current year.
AMLX Trading at 81.58% from the 50-Day Moving Average
After a stumble in the market that brought AMLX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.56% of loss for the given period.
Volatility was left at 11.29%, however, over the last 30 days, the volatility rate increased by 6.87%, as shares surge +95.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +223.21% upper at present.
During the last 5 trading sessions, AMLX rose by +25.09%, which changed the moving average for the period of 200-days by -52.99% in comparison to the 20-day moving average, which settled at $4.97. In addition, Amylyx Pharmaceuticals Inc saw -54.69% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AMLX starting from Klee Justin B., who sale 18,589 shares at the price of $3.20 back on Sep 30 ’24. After this action, Klee Justin B. now owns 3,120,569 shares of Amylyx Pharmaceuticals Inc, valued at $59,429 using the latest closing price.
Cohen Joshua B, the Co-Chief Executive Officer of Amylyx Pharmaceuticals Inc, sale 18,589 shares at $3.20 during a trade that took place back on Sep 30 ’24, which means that Cohen Joshua B is holding 3,220,569 shares at $59,414 based on the most recent closing price.
Stock Fundamentals for AMLX
Current profitability levels for the company are sitting at:
- -1.27 for the present operating margin
- 0.32 for the gross margin
The net margin for Amylyx Pharmaceuticals Inc stands at -1.32. The total capital return value is set at -1.27. Equity return is now at value -51.22, with -42.22 for asset returns.
Based on Amylyx Pharmaceuticals Inc (AMLX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -37.04. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -72.13.
Currently, EBITDA for the company is 39.89 million with net debt to EBITDA at 0.28. When we switch over and look at the enterprise to sales, we see a ratio of 1.99. The receivables turnover for the company is 113.51for trailing twelve months and the total asset turnover is 0.78. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.66.
Conclusion
To sum up, Amylyx Pharmaceuticals Inc (AMLX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
